DURECT Corporation (NASDAQ:DRRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Monday, May 22nd. They currently have a $3.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 129.01% from the company’s previous close.
Shares of DURECT Corporation (DRRX) traded up 0.77% during mid-day trading on Monday, reaching $1.31. 709,238 shares of the company traded hands. The company’s market capitalization is $185.98 million. The stock’s 50-day moving average is $1.15 and its 200-day moving average is $1.11. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $2.00.
DURECT Corporation (NASDAQ:DRRX) last posted its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). DURECT Corporation had a negative net margin of 232.05% and a negative return on equity of 318.49%. The firm had revenue of $4.57 million during the quarter, compared to the consensus estimate of $3.60 million. On average, equities analysts predict that DURECT Corporation will post ($0.23) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/06/16/hc-wainwright-reaffirms-buy-rating-for-durect-co-drrx-updated-updated.html.
Several large investors have recently modified their holdings of DRRX. State Street Corp increased its stake in shares of DURECT Corporation by 2.5% in the fourth quarter. State Street Corp now owns 1,919,694 shares of the specialty pharmaceutical company’s stock worth $2,570,000 after buying an additional 46,450 shares during the period. Broadfin Capital LLC increased its stake in shares of DURECT Corporation by 33.0% in the fourth quarter. Broadfin Capital LLC now owns 8,506,229 shares of the specialty pharmaceutical company’s stock worth $11,398,000 after buying an additional 2,111,023 shares during the period. Kettle Hill Capital Management LLC purchased a new stake in shares of DURECT Corporation during the fourth quarter worth approximately $506,000. Stonepine Capital Management LLC increased its stake in shares of DURECT Corporation by 32.3% in the fourth quarter. Stonepine Capital Management LLC now owns 2,177,791 shares of the specialty pharmaceutical company’s stock worth $2,918,000 after buying an additional 531,621 shares during the period. Finally, Ingalls & Snyder LLC increased its stake in shares of DURECT Corporation by 1.3% in the first quarter. Ingalls & Snyder LLC now owns 2,050,082 shares of the specialty pharmaceutical company’s stock worth $2,153,000 after buying an additional 26,000 shares during the period. Institutional investors and hedge funds own 49.45% of the company’s stock.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.